A vs. JAZZ: Agilent vs. Jazz Pharmaceuticals Stock Comparison

November 11, 2026

How do Agilent (A) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while JAZZ is classified in Pharmaceuticals.

Company profile comparison for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Profile Item	A	JAZZ
Name	AgileThought, Inc. Class A Common Stock	Jazz Pharmaceuticals plc
Country/Region	United States	Ireland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	49.28 billion USD	15.07 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 18, 1999	June 1, 2007
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

JAZZ

GSPC

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and Jazz Pharmaceuticals (JAZZ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and Jazz Pharmaceuticals (JAZZ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
Total Return (1Y)	22.92%	84.44%
Total Return (3Y, Annualized)	19.33%	27.57%
Total Return (5Y, Annualized)	3.03%	12.88%

Risk Profile

Drawdown History

JAZZ

GSPC

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and Jazz Pharmaceuticals (JAZZ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
Volatility (1Y, Annualized)	33.10%	38.74%
Beta (5Y)	1.22	0.33
Max Drawdown (5Y)	-38.09%	-42.03%
Avg. Volume (3M)	2.25M	878.80K

Risk-Adjusted Performance

Risk-Return Positioning

A and JAZZ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
Sharpe Ratio (1Y)	0.56	2.07
Sortino Ratio (1Y)	0.96	4.14

Profitability

ROE (TTM)

Agilent (A) at 20.97% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.05%

Max: 109.18%
Q3: 6.23%
JAZZ: 5.05%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.37%

Max: 18.05%
Q3: 4.78%
JAZZ: 4.37%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.17%

Max: 83.12%
JAZZ: 30.17%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
ROE (TTM)	20.97%	5.05%
ROA (TTM)	8.63%	6.92%
Net Margin (TTM)	19.53%	4.37%
Operating Margin (TTM)	25.56%	30.17%
Gross Margin (TTM)	53.65%	91.10%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Agilent (A) at 3.16% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
Revenue Growth (YoY)	6.73%	4.88%
Revenue Growth (3Y CAGR)	0.48%	5.26%
EPS Growth (YoY)	3.16%	-167.51%
EPS Growth (3Y CAGR)	3.02%	--

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.82

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JAZZ: 1.82
Min: 0.10

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 1.42
JAZZ: 1.35
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
Current Ratio (MRQ)	2.05	1.82
Debt / Equity (MRQ)	0.56	1.35
Net Debt / EBITDA	1.15	1.39

Dividends

Dividend Yield (TTM)

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

JAZZ: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

JAZZ: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
Dividend Yield (TTM)	0.59%	0.00%
Dividend Payout Ratio (TTM)	19.98%	0.00%

Valuation

P/E Ratio (TTM)

Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

69.46

Max: 85.34
JAZZ: 69.46
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.19

Max: 58.18
Q3: 25.77
Median: 7.30
JAZZ: 3.19
Q1: 3.01
Min: 0.01

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.59

Max: 13.53
Q3: 6.54
JAZZ: 3.59
Median: 3.25
Q1: 1.69
Min: -5.59

Agilent (A) vs. Jazz Pharmaceuticals (JAZZ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Jazz Pharmaceuticals (JAZZ)
Metric	A	JAZZ
P/E Ratio (TTM)	34.47	69.46
P/S Ratio (TTM)	6.68	3.19
P/B Ratio (MRQ)	6.69	3.59
Free Cash Flow Yield (TTM)	2.15%	11.16%